Nalmefene, Given as Needed, in the Routine Treatment of Patients with Alcohol Dependence: An Interventional, Open-Label Study in Primary Care | Zendy

Philippe Castéra | Zendy; Edmund Stewart | Zendy; Josef Großkopf | Zendy; Carlos Brotons | Zendy; Maiken Brix Schou | Zendy; Doris Zhang | Zendy; Björn Steiniger Brach | Zendy; Didier Meulien | Zendy

Open Access

Nalmefene, Given as Needed, in the Routine Treatment of Patients with Alcohol Dependence: An Interventional, Open-Label Study in Primary Care

Author(s) -

Philippe Castéra,

Edmund Stewart,

Josef Großkopf,

Carlos Brotons,

Maiken Brix Schou,

Doris Zhang,

Björn Steiniger Brach,

Didier Meulien

Publication year - 2018

Publication title -

european addiction research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.862

H-Index - 54

eISSN - 1421-9891

pISSN - 1022-6877

DOI - 10.1159/000494692

Subject(s) - medicine , cohort , nalmefene , psychosocial , adverse effect , nausea , cohort study , alcohol , pediatrics , psychiatry , naltrexone , receptor , opioid , biochemistry , chemistry

This 12-week, open-label, primary care study (NCT02195817) evaluated the efficacy and safety of nalmefene, taken as needed, to reduce alcohol consumption in adults with a diagnosis of alcohol dependence and drinking at least at high drinking risk levels (DRL, > 60 g/day for men, > 40 g/day for women).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research